In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Caris Life Sciences trades at $24.49, well above the PERT-weighted fair value of $11.36, implying a 53.6% overvaluation with high confidence. Significant negative DCF estimates contrast with modest analyst targets and high liquidity but zero profitability and efficiency scores. The zero downside risk in Monte Carlo scenarios suggests limited price erosion despite valuation concerns.